Please assess the completion status of the following clinical trial:

Trial Title: Somatropin Treatment to Final Height in Turner Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* girl with Turner syndrome~* prepubertal, Tanner stage I breast~* height velocity less than 6 cm/year and height less than or equal to the tenth percentile for sex and age in general population~* at least 6 months (preferably 12 months) of accurate height measurements available for calculation of pre-study height velocity~* if thyroxine deficient, to have received replacement therapy, and for six months prior to enrollment have had normal thyroid function tests~Exclusion Criteria:~* prior treatment with growth hormone~* presence of a Y component in karyotype with gonads in situ~* diabetes mellitus

- Gender: FEMALE
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
- Humatrope (Type: EXPERIMENTAL): Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).

Based on this trial design, predict the completion outcome and termination type (if applicable).